Mechanism of inhibition of platelet aggregation by HCL-31D

European Journal of Pharmacology

Volumn 387, Issue 2, 2000, Pages 125-131

  Chou, Tz Chong ^a   Li, Chi Yuan ^a   Lee, An Rong ^a   Wu, Tzong Ming ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

cAMP; HCL 31D, platelet aggregation; Phosphoinositide breakdown; Thromboxane B2

Indexed keywords

4,5 DIHYDRO 6 [4 [2 HYDROXY 3 (3,4 DIMETHOXYBENZYLAMINO)PROPOXY]NAPHTH 1 YL] 3(2H) PYRIDAZINONE; ADENOSINE TRIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; CYCLIC AMP; ISOBUTYLMETHYLXANTHINE; PHOSPHATIDYLINOSITIDE; PROSTAGLANDIN E1; PROSTAGLANDIN SYNTHASE; PYRIDAZINONE DERIVATIVE; THROMBIN; THROMBOXANE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; NONHUMAN; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE TRIPHOSPHATE; ANIMALS; CALCIUM; CYCLIC AMP; CYCLIC GMP; PHOSPHATIDYLINOSITOLS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROPANOLAMINES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRIDAZINES; RABBITS; THROMBOXANE B2; THROMBOXANE-A SYNTHASE;

EID: 0033958833     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00812-2     Document Type: Article

References (33)

1. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;81-106.
2. Bell R.L., Kennerly D.A., Stanford N., Majeru P.W. Diglyceride lipase: a pathway for arachidonic acid release from human platelets. Proc. Natl. Acad. Sci. U.S.A. 76:1979;1790-1792.
3. Benjamin C.W., Lin A.H., Morris J., Wishka D.G., Gorman R.R. 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity. J. Pharmacol. Exp. Ther. 265:1992;457-462.
4. Berridge M.J. Inositol triphosphate, diacylglycerol as second messenger. Biochem. J. 220:1984;345-360.
5. 2 activity specific for phosphatidic acid: a possible mechanism for the production of arachidonic acid in platelets. J. Biol. Chem. 256:1981;5399-5403.
6. Buerke M., Cyrus T., Darius H. Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation in vivo and in vitro. Thromb. Res. 88:1997;89-98.
7. Chou T.-C., Hsu L.-Y., Yen M.-H., Ding Y.-A. The inhibitory effect of 2-thienyl 2′ hydroxyphenyl ketone (C85) on platelet thromboxane formation. Thromb. Res. 84:1996;83-95.
8. DeLuca M., McElory W.D. Purification and properties of firefly luciferase. Methods Enzymol. 57:1978;3-15.
9. Enouff J., Giraud F., Bredoux R., Bordeau N., Sarkadi B., Levy-Toledano S. Stimulation of the 23-kd protein cAMP dependent phosphorylation by inositol 1,4,5, triphosphate in human platelet membrane vesicles. Biochem. Biophys. Res. Commun. 145:1987;139-145.
10. Feinstein M.B., Zavoico G.B., Halenda S.P. Calcium and cyclic AMP: antagonistic modulators of platelet function. Longerecker G.L. The Platelets - Physiology and Pharmacology. 1985;237-269 Academic Press, Orlando.
11. Fitzgerald D.J. Platelet activation in the pathogenesis of unstable angina: importance in determining the response to plasminogen activators. Am. J. Cardiol. 68:1991;51B-57B.
12. 2 as an amplifying signal for other agonists. Am. J. Cardiol. 68:1991;11B-15B.
13. Geiger J., Nolte C., Butt E., Sage S.O., Walter U. Role of cGMP and cAMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc. Natl. Acad. Sci. U.S.A. 89:1992;1031-1035.
14. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
15. Hamberg M., Suensson J., Samuelsson J. Thromboxanes: a new group of biological active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. U.S.A. 72:1975;2994-2998.
16. Lapetina E.G. Incorporation of synthetic 1,2-diacylglycerol into platelet phosphatidylinositol is increased by cyclic AMP. FEBS Lett. 195:1986;111-114.
17. Lejemtel T.H., Keung E., Ribner H.S., Davis R., Wexler J., Blaufox M.D., Sonnenblick E.H. Sustained beneficial effects of oral amrinone on cardiac and renal function in patients. Am. J. Cardiol. 45:1980;123-129.
18. Lerea K.M., Glonset J.A., Krebs E.G. Agents that elevate cAMP levels in platelets decrease thrombin binding. J. Biol. Chem. 262:1987;282-288.
19. Liu M., Simon M. Regulation by cAMP-dependent protein kinase of G-protein-mediated phospholipase C. Nature. 382:1996;83-87.
20. Marcus A.J., Safier L.B. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J. 349:1993;107-114.
21. Maskin C.S., Forman R., Klein N.A., Sonnenblick E.H., Lejemtel T.H. Long-term amrinone therapy in patients with severe congestive heart failure. Am. J. Med. 72:1982;113-118.
22. Minkes M., Stanford N., Chi M.M., Roth G.J., Raz A., Needleman P., Majerus P.W. Cyclic adenosine 3′,5′-monophosphate inhibits the availability of arachidonic to prostaglandin synthase in human platelets suspensions. J. Clin. Invest. 59:1977;449-454.
23. Mustard J.F. Function of platelets and their role in thrombosis. Trans. Am. Clin. Climatol. Assoc. 87:1976;104-127.
24. Neylon C.B., Summers R.J. Stimulation of a1-adrenoceptors in rat kidney mediates increased inositol phospholipid hydrolysis. Br. J. Pharmacol. 91:1987;367-376.
25. 2+ transporting membrane vesicle fraction derived from human platelets. J. Biol. Chem. 260:1985;956-962.
26. 2+ store: studies using Fura-2. Biochem. Biophys. Res. Commun. 139:1986;308-314.
27. Rhee S.G., Lee C.W., John D.Y. Phospholipase C isoenzymes and modulation by cyclic AMP-dependent protein kinase. Adv. Second Messenger Phospholipase Res. 28:1993;57-64.
28. Ryningen A., Jensen B.O., Holmsen H. Elevation of cyclic AMP decreases phosphoinositide turnover and inhibits thrombin-induced secretion in human platelets. Biochim. Biophys. Acta. 1394:1998;235-248.
29. Siess W. Molecular mechanisms of platelet activation. Physiol. Rev. 69:1989;58-178.
30. Siess W., Lapetina E.G. Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition. Biochem. J. 271:1990;815-819.
31. Somlyo A.P., Somlyo A.V. Signal transduction and regulation in smooth muscle. Nature. 372:1994;231-236.
32. 2-mediated arachidonic acid release by cyclic AMP defines a negative feedback loop for P2Y receptor activation in Madin-Darby canine kidney D1 cells. J. Biol. Chem. 274(15):1999;10035-10038.
33. 2+ in platelets is controlled by cyclic AMP: antagonism between stimulators and inhibitors of adenylate cyclase. Biochem. Biophys. Res. Commun. 120:1984;579-585.